Armin Ghobadi, MD, on How to Interpret Preliminary Data in Patients with DLBCL

Video

Ghobadi expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 ASH Annual Meeting.

In an interview with CancerNetwork®, Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, detailed which data can be trusted and expressed caution about interpreting efficacy data from a phase 1 pilot study presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

[With a] phase 1 pilot trial, obviously the goal of them is just showing feasibility and safety. You can’t look at the efficacy data from phase 1. You can obviously look at these 10 patients and see how this is effective in this scenario and those kinds of things. I think we see signs of them based on the correlative studies that we did that are interesting in terms of activated T-cells, CD8-to-CD4 ratio, and early on post BEAM [carmustine, etoposide, cytarabine and melphalan] autologous transplant. One hundred percent [of patients are] MRD negative after autologous transplant, [but] you cannot translate that to 100% of people are going to be cured…because that’s not the case. Most likely, this patient will need more than 1 cycle of treatment; several cycles of this T-cell engager at various time points [is] easily given. You can’t look at the result of this and focus on the efficacy end point, basically.

Related Videos
The education of patients on identifying and reporting adverse effects is a critical part of effective toxicity management.
One role of a physician assistant is to help patients understand their treatment and the results they’re presented with.
Adverse effect management is a concern for clinicians when administering follicular lymphoma treatment, and the use of targeted pathways may help mitigate them.
Andre H. Goy, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on B-cell malignancies
Andrew Ip, MD, an expert on diffuse large B-cell lymphoma
Andre Goy, MD, an expert on mantle cell lymphoma
André Goy, MD, an expert on B-cell malignancies
Related Content